VIVES is a multi-sector fund that invests in projects with a positive societal impact
Botalys has developed a vertical farming technology that enables the production of rare plants and high-value ingredients for the food supplement, cosmetics, and pharmaceutical industries. This...
Generare is unlocking nature’s untapped potential, turning the complexity of microbial DNA into a scalable platform that can transform drug discovery.
By combining advanced biotechnology with data...
The result of more than 15 years of research in the university laboratories of UCLouvain and multiple collaborations (ELEN department, ICTEAM), the VOCSens spin-off is developing a new concept of...
Eric de La Fortelle, Venture Partner at Seventure Partners:
"The tech transfer organization SOPARTEC and the associated fund VIVES played a key role in the initial structuring and the foundation of...
Vincent Mouret, Chairman of the Board of Cissoid:
"As Chairman of the board of Cissoid, I’ve been working closely to VIVES for the last 10 years. I have really appreciated VIVES involvement and...
Pierre Blondeau, CEO Upstreem:
"We have been working since 2017 with VIVES II, which has joined us since the beginning of our adventure. VIVES II team has an in-depth understanding of all aspects of...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is
NVD003 is a bone grafting material developed to surgically treat patients with Congenital Pseudarthrosis of the Tibia, a rare and difficult-to-treat pediatric disease
Four young patients were treated